Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintas-Cardama, J Mercer… - Leukemia, 2013 - nature.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy
R Naser, H Dilabazian, H Bahr… - Oncology …, 2022 - spandidos-publications.com
Cancer still ranks as one of the top causes of morbidity and mortality despite recent
improvements in standard chemotherapy, radiotherapy, and surgery. This underlines some …
improvements in standard chemotherapy, radiotherapy, and surgery. This underlines some …
[HTML][HTML] High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of …
F Guilhot, B Druker, RA Larson, I Gathmann, C So… - …, 2009 - ncbi.nlm.nih.gov
Background Imatinib is the standard of care for newly diagnosed chronic-phase chronic
myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS …
myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS …
Interferon alpha for treatment of chronic myeloid leukemia
B Simonsson, H Hjorth-Hansen… - Current drug …, 2011 - ingentaconnect.com
Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …
Current status of antivascular therapy and targeted treatment in the clinic
O Dahl, ED Borkamo, Ø Fluge - International journal of …, 2008 - Taylor & Francis
Antivascular and targeted therapy are now an integrated part of the treatment of
myelogenous leukemias, GIST tumours, B-cell lymphomas and breast cancer. In various …
myelogenous leukemias, GIST tumours, B-cell lymphomas and breast cancer. In various …
Current awareness: Pharmacoepidemiology and drug safety
John Wiley & Sons, Ltd. - 2003 - Wiley Online Library
In order to keep subscribers up‐to‐date with the latest developments in their field, John
Wiley & Sons are providing a current awareness service in each issue of the journal. The …
Wiley & Sons are providing a current awareness service in each issue of the journal. The …
Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?
DT Yeung, S Branford - Hematology 2010, the American …, 2012 - ashpublications.org
An 80-year-old man has newly diagnosed chronic myeloid leukemia. His BM and blood
examination at diagnosis confirms chronic-phase disease, with the Philadelphia …
examination at diagnosis confirms chronic-phase disease, with the Philadelphia …
[PDF][PDF] PHILADELPHIA CHROMOSOME IN PRETHERAPEUTIC CASES OF CHRONIC MYELOGENOUS LEUKEMIA
MK Naik, DN Mishra, S Rout, P Panda… - International Journal …, 2016 - researchgate.net
Chronic myeloid leukemia (CML) is a clonal myel0 proliferative disorder due to neoplastic
transformation of myeloid stem cells. The characteristic Philadelphia Chromosome …
transformation of myeloid stem cells. The characteristic Philadelphia Chromosome …
[PDF][PDF] Comparison of long-term outcome of early versus late chronic phase imatinib receivers
E Gürkan, S Paydas - Journal of Hematological Malignancies, 2012 - academia.edu
The introduction of imatinib mesylate made a remarkable contribution to the management of
patients with chronic myeloid leukemia. In this study, we assessed the long-term efficacy of …
patients with chronic myeloid leukemia. In this study, we assessed the long-term efficacy of …